Identification of the estrogen receptor beta as a possible new tamoxifen-sensitive target in diffuse large B-cell lymphoma
Last Updated: Tuesday, March 22, 2022
Based on data showing that estrogen receptor beta (ERβ) is expressed at significantly higher levels in DLBCL compared to normal B cells, and that breast cancer patients who received tamoxifen had a significantly reduced risk for DLBCL compared to those who did not receive tamoxifen, researchers encourage the investigation of tamoxifen for the treatment of DLBCL.
Advertisement
News & Literature Highlights
